77.93
+4.90%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BridgeBio Pharma
From its filings with the US Securities and Exchange Commission
BridgeBio Pharma is based in Palo Alto, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BBIO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $502.1m and a net loss of $732.9m. At that date it held total assets of $936.0m and shareholders' equity of −$2.09bn. By business, Net product revenue brought in 72.2% of revenue, followed by License and services revenue at 25.6% and Royalty revenue at 2.3%.
BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs.
Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory approval and commercialization. To date, more than 8,500 patients have been treated with our approved medicines, and we have obtained U.S. Food and Drug Administration (the “FDA”) approval for three products. We believe our decentralized hub and spoke model enables us to achieve clinical proof-of-concept with speed and efficiency, demonstrated by an average investment per program of less than $40.0 million to proof-of-concept data and less than $10.0 million to reach Investigational New Drug (“IND”) submission. This efficiency allows us to work on a broad range of scientifically compelling therapies, including programs for underserved conditions which more traditional biopharmaceutical models might leave on the shelf but we believe can be developed on a Net Present Value (“NPV”)-positive basis in our portfolio.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 27 Jun 2019
- Employees
- 834
- Website
- bridgebio.com ↗
- Head office
- 3160 PORTER DR., PALO ALTO, CA, 94304
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Thomas TrimarchiPresident, Chief Financial Officer$6.5m
- Dr. Neil KumarChief Executive Officer, Director, since 2015$15.6m
- Dr. Charles HomcyLead Director, Chairman of Pharmaceuticals, since 2018$1.1m
- Mr. Fred HassanLead Independent Director$599,998
- Dr. Frank MccormickDirector, since 2019$1.1m
- Dr. Eric AguiarIndependent Director$599,998
- Ms. Jennifer CookIndependent Director$599,998
- Mr. Douglas DachilleIndependent Director$599,998
- Mr. Ronald DanielsIndependent Director$599,998
- Mrs. Andrea EllisIndependent Director$599,998
- Dr. Andrew LoIndependent Director$649,998
- Mr. James MomtazeeIndependent Director$599,998
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 29
- Environment
- 29
- Social
- 33
- Governance
- 26
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BridgeBio Pharma Inc has several strengths that contribute to its competitive advantage:
- Despite its strengths, BridgeBio Pharma Inc faces certain weaknesses that pose challenges:
- BridgeBio Pharma Inc can leverage the following opportunities to drive growth and expansion:
- BridgeBio Pharma Inc should be aware of the following threats in its operating environment:
Weaknesses
- Despite its strengths, BridgeBio Pharma Inc faces certain weaknesses that pose challenges:
- BridgeBio Pharma Inc can leverage the following opportunities to drive growth and expansion:
- BridgeBio Pharma Inc should be aware of the following threats in its operating environment:
Opportunities
- BridgeBio Pharma Inc can leverage the following opportunities to drive growth and expansion:
- BridgeBio Pharma Inc should be aware of the following threats in its operating environment:
Threats
- BridgeBio Pharma Inc should be aware of the following threats in its operating environment:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.